nodes	percent_of_prediction	percent_of_DWPC	metapath
Methyldopa—Amenorrhoea—Mechlorethamine—lymphatic system cancer	0.0278	0.0278	CcSEcCtD
Methyldopa—Bone marrow depression—Teniposide—lymphatic system cancer	0.0267	0.0267	CcSEcCtD
Methyldopa—VIIth nerve paralysis—Carmustine—lymphatic system cancer	0.0247	0.0247	CcSEcCtD
Methyldopa—VIIth nerve paralysis—Vincristine—lymphatic system cancer	0.0236	0.0236	CcSEcCtD
Methyldopa—Bone marrow depression—Fludarabine—lymphatic system cancer	0.0234	0.0234	CcSEcCtD
Methyldopa—Haemolytic anaemia—Mechlorethamine—lymphatic system cancer	0.0196	0.0196	CcSEcCtD
Methyldopa—Pancytopenia—Mechlorethamine—lymphatic system cancer	0.0146	0.0146	CcSEcCtD
Methyldopa—Haemolytic anaemia—Teniposide—lymphatic system cancer	0.0145	0.0145	CcSEcCtD
Methyldopa—Bone marrow depression—Vincristine—lymphatic system cancer	0.0143	0.0143	CcSEcCtD
Methyldopa—Bone marrow depression—Mitoxantrone—lymphatic system cancer	0.014	0.014	CcSEcCtD
Methyldopa—Jaundice—Mechlorethamine—lymphatic system cancer	0.0133	0.0133	CcSEcCtD
Methyldopa—Tenderness—Bleomycin—lymphatic system cancer	0.0133	0.0133	CcSEcCtD
Methyldopa—Agranulocytosis—Mechlorethamine—lymphatic system cancer	0.0128	0.0128	CcSEcCtD
Methyldopa—Cardiac failure congestive—Fludarabine—lymphatic system cancer	0.0127	0.0127	CcSEcCtD
Methyldopa—Liver function test abnormal—Teniposide—lymphatic system cancer	0.0121	0.0121	CcSEcCtD
Methyldopa—Pericarditis—Methotrexate—lymphatic system cancer	0.0109	0.0109	CcSEcCtD
Methyldopa—Pancytopenia—Teniposide—lymphatic system cancer	0.0107	0.0107	CcSEcCtD
Methyldopa—Amenorrhoea—Mitoxantrone—lymphatic system cancer	0.0107	0.0107	CcSEcCtD
Methyldopa—Liver function test abnormal—Fludarabine—lymphatic system cancer	0.0106	0.0106	CcSEcCtD
Methyldopa—Toxic epidermal necrolysis—Fludarabine—lymphatic system cancer	0.0103	0.0103	CcSEcCtD
Methyldopa—Angina pectoris—Fludarabine—lymphatic system cancer	0.00967	0.00967	CcSEcCtD
Methyldopa—Leukopenia—Mechlorethamine—lymphatic system cancer	0.00956	0.00956	CcSEcCtD
Methyldopa—Pancytopenia—Fludarabine—lymphatic system cancer	0.00943	0.00943	CcSEcCtD
Methyldopa—Gynaecomastia—Carmustine—lymphatic system cancer	0.00906	0.00906	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Mechlorethamine—lymphatic system cancer	0.00903	0.00903	CcSEcCtD
Methyldopa—Infection—Mechlorethamine—lymphatic system cancer	0.00866	0.00866	CcSEcCtD
Methyldopa—Thrombocytopenia—Mechlorethamine—lymphatic system cancer	0.00853	0.00853	CcSEcCtD
Methyldopa—Skin disorder—Mechlorethamine—lymphatic system cancer	0.00847	0.00847	CcSEcCtD
Methyldopa—Cardiac failure congestive—Mitoxantrone—lymphatic system cancer	0.00754	0.00754	CcSEcCtD
Methyldopa—Leukopenia—Teniposide—lymphatic system cancer	0.00705	0.00705	CcSEcCtD
Methyldopa—Bone marrow depression—Methotrexate—lymphatic system cancer	0.00695	0.00695	CcSEcCtD
Methyldopa—Pancytopenia—Bleomycin—lymphatic system cancer	0.00692	0.00692	CcSEcCtD
Methyldopa—Liver disorder—Methotrexate—lymphatic system cancer	0.00688	0.00688	CcSEcCtD
Methyldopa—Liver function test abnormal—Carmustine—lymphatic system cancer	0.00679	0.00679	CcSEcCtD
Methyldopa—Oedema—Teniposide—lymphatic system cancer	0.00643	0.00643	CcSEcCtD
Methyldopa—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00642	0.00642	CcSEcCtD
Methyldopa—Infection—Teniposide—lymphatic system cancer	0.00638	0.00638	CcSEcCtD
Methyldopa—Thrombocytopenia—Teniposide—lymphatic system cancer	0.00629	0.00629	CcSEcCtD
Methyldopa—Leukopenia—Fludarabine—lymphatic system cancer	0.00619	0.00619	CcSEcCtD
Methyldopa—Pancytopenia—Carmustine—lymphatic system cancer	0.00604	0.00604	CcSEcCtD
Methyldopa—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00596	0.00596	CcSEcCtD
Methyldopa—Arthralgia—Fludarabine—lymphatic system cancer	0.00589	0.00589	CcSEcCtD
Methyldopa—Myalgia—Fludarabine—lymphatic system cancer	0.00589	0.00589	CcSEcCtD
Methyldopa—Pancytopenia—Vincristine—lymphatic system cancer	0.00576	0.00576	CcSEcCtD
Methyldopa—Oedema—Fludarabine—lymphatic system cancer	0.00565	0.00565	CcSEcCtD
Methyldopa—Pancytopenia—Mitoxantrone—lymphatic system cancer	0.00561	0.00561	CcSEcCtD
Methyldopa—Infection—Fludarabine—lymphatic system cancer	0.00561	0.00561	CcSEcCtD
Methyldopa—Erectile dysfunction—Vincristine—lymphatic system cancer	0.00559	0.00559	CcSEcCtD
Methyldopa—Vomiting—Mechlorethamine—lymphatic system cancer	0.00554	0.00554	CcSEcCtD
Methyldopa—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00554	0.00554	CcSEcCtD
Methyldopa—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.00553	0.00553	CcSEcCtD
Methyldopa—Rash—Mechlorethamine—lymphatic system cancer	0.0055	0.0055	CcSEcCtD
Methyldopa—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00549	0.00549	CcSEcCtD
Methyldopa—Erectile dysfunction—Mitoxantrone—lymphatic system cancer	0.00544	0.00544	CcSEcCtD
Methyldopa—Weight increased—Mitoxantrone—lymphatic system cancer	0.00538	0.00538	CcSEcCtD
Methyldopa—Nausea—Mechlorethamine—lymphatic system cancer	0.00518	0.00518	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00515	0.00515	CcSEcCtD
Methyldopa—Jaundice—Mitoxantrone—lymphatic system cancer	0.00514	0.00514	CcSEcCtD
Methyldopa—Body temperature increased—Teniposide—lymphatic system cancer	0.00508	0.00508	CcSEcCtD
Methyldopa—Paraesthesia—Fludarabine—lymphatic system cancer	0.00507	0.00507	CcSEcCtD
Methyldopa—Connective tissue disorder—Carmustine—lymphatic system cancer	0.005	0.005	CcSEcCtD
Methyldopa—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.00492	0.00492	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00488	0.00488	CcSEcCtD
Methyldopa—Constipation—Fludarabine—lymphatic system cancer	0.00483	0.00483	CcSEcCtD
Methyldopa—Bradycardia—Mitoxantrone—lymphatic system cancer	0.00481	0.00481	CcSEcCtD
Methyldopa—Vasculitis—Methotrexate—lymphatic system cancer	0.00481	0.00481	CcSEcCtD
Methyldopa—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00477	0.00477	CcSEcCtD
Methyldopa—Hypersensitivity—Teniposide—lymphatic system cancer	0.00473	0.00473	CcSEcCtD
Methyldopa—Hepatitis—Mitoxantrone—lymphatic system cancer	0.00473	0.00473	CcSEcCtD
Methyldopa—Asthenia—Teniposide—lymphatic system cancer	0.00461	0.00461	CcSEcCtD
Methyldopa—Leukopenia—Bleomycin—lymphatic system cancer	0.00454	0.00454	CcSEcCtD
Methyldopa—Cardiac disorder—Vincristine—lymphatic system cancer	0.00451	0.00451	CcSEcCtD
Methyldopa—Body temperature increased—Fludarabine—lymphatic system cancer	0.00446	0.00446	CcSEcCtD
Methyldopa—Mental disorder—Carmustine—lymphatic system cancer	0.00446	0.00446	CcSEcCtD
Methyldopa—Angiopathy—Vincristine—lymphatic system cancer	0.00441	0.00441	CcSEcCtD
Methyldopa—Diarrhoea—Teniposide—lymphatic system cancer	0.0044	0.0044	CcSEcCtD
Methyldopa—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00438	0.00438	CcSEcCtD
Methyldopa—Myalgia—Bleomycin—lymphatic system cancer	0.00432	0.00432	CcSEcCtD
Methyldopa—Mental disorder—Vincristine—lymphatic system cancer	0.00425	0.00425	CcSEcCtD
Methyldopa—Gynaecomastia—Methotrexate—lymphatic system cancer	0.0042	0.0042	CcSEcCtD
Methyldopa—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00416	0.00416	CcSEcCtD
Methyldopa—Oedema—Bleomycin—lymphatic system cancer	0.00414	0.00414	CcSEcCtD
Methyldopa—Infection—Bleomycin—lymphatic system cancer	0.00411	0.00411	CcSEcCtD
Methyldopa—Vomiting—Teniposide—lymphatic system cancer	0.00409	0.00409	CcSEcCtD
Methyldopa—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00405	0.00405	CcSEcCtD
Methyldopa—Asthenia—Fludarabine—lymphatic system cancer	0.00405	0.00405	CcSEcCtD
Methyldopa—Rash—Teniposide—lymphatic system cancer	0.00405	0.00405	CcSEcCtD
Methyldopa—Dermatitis—Teniposide—lymphatic system cancer	0.00405	0.00405	CcSEcCtD
Methyldopa—Headache—Teniposide—lymphatic system cancer	0.00403	0.00403	CcSEcCtD
Methyldopa—Leukopenia—Carmustine—lymphatic system cancer	0.00396	0.00396	CcSEcCtD
Methyldopa—Diarrhoea—Fludarabine—lymphatic system cancer	0.00386	0.00386	CcSEcCtD
Methyldopa—Nausea—Teniposide—lymphatic system cancer	0.00382	0.00382	CcSEcCtD
Methyldopa—Leukopenia—Vincristine—lymphatic system cancer	0.00378	0.00378	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00377	0.00377	CcSEcCtD
Methyldopa—Myalgia—Carmustine—lymphatic system cancer	0.00377	0.00377	CcSEcCtD
Methyldopa—Paraesthesia—Bleomycin—lymphatic system cancer	0.00372	0.00372	CcSEcCtD
Methyldopa—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00369	0.00369	CcSEcCtD
Methyldopa—Oedema—Carmustine—lymphatic system cancer	0.00361	0.00361	CcSEcCtD
Methyldopa—Myalgia—Vincristine—lymphatic system cancer	0.0036	0.0036	CcSEcCtD
Methyldopa—Infection—Carmustine—lymphatic system cancer	0.00359	0.00359	CcSEcCtD
Methyldopa—Vomiting—Fludarabine—lymphatic system cancer	0.00359	0.00359	CcSEcCtD
Methyldopa—Rash—Fludarabine—lymphatic system cancer	0.00356	0.00356	CcSEcCtD
Methyldopa—Dermatitis—Fludarabine—lymphatic system cancer	0.00356	0.00356	CcSEcCtD
Methyldopa—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00354	0.00354	CcSEcCtD
Methyldopa—Headache—Fludarabine—lymphatic system cancer	0.00354	0.00354	CcSEcCtD
Methyldopa—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00351	0.00351	CcSEcCtD
Methyldopa—Myalgia—Mitoxantrone—lymphatic system cancer	0.00351	0.00351	CcSEcCtD
Methyldopa—Oedema—Vincristine—lymphatic system cancer	0.00345	0.00345	CcSEcCtD
Methyldopa—Infection—Vincristine—lymphatic system cancer	0.00343	0.00343	CcSEcCtD
Methyldopa—Nervous system disorder—Vincristine—lymphatic system cancer	0.00338	0.00338	CcSEcCtD
Methyldopa—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00338	0.00338	CcSEcCtD
Methyldopa—Oedema—Mitoxantrone—lymphatic system cancer	0.00336	0.00336	CcSEcCtD
Methyldopa—Nausea—Fludarabine—lymphatic system cancer	0.00335	0.00335	CcSEcCtD
Methyldopa—Infection—Mitoxantrone—lymphatic system cancer	0.00334	0.00334	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00329	0.00329	CcSEcCtD
Methyldopa—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00329	0.00329	CcSEcCtD
Methyldopa—Body temperature increased—Bleomycin—lymphatic system cancer	0.00327	0.00327	CcSEcCtD
Methyldopa—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00326	0.00326	CcSEcCtD
Methyldopa—Paraesthesia—Carmustine—lymphatic system cancer	0.00325	0.00325	CcSEcCtD
Methyldopa—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.00314	0.00314	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00314	0.00314	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00312	0.00312	CcSEcCtD
Methyldopa—Paraesthesia—Vincristine—lymphatic system cancer	0.0031	0.0031	CcSEcCtD
Methyldopa—Constipation—Carmustine—lymphatic system cancer	0.00309	0.00309	CcSEcCtD
Methyldopa—Breast disorder—Methotrexate—lymphatic system cancer	0.00308	0.00308	CcSEcCtD
Methyldopa—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.00307	0.00307	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00306	0.00306	CcSEcCtD
Methyldopa—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00305	0.00305	CcSEcCtD
Methyldopa—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00302	0.00302	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00298	0.00298	CcSEcCtD
Methyldopa—Asthenia—Bleomycin—lymphatic system cancer	0.00297	0.00297	CcSEcCtD
Methyldopa—Constipation—Vincristine—lymphatic system cancer	0.00295	0.00295	CcSEcCtD
Methyldopa—Eosinophilia—Methotrexate—lymphatic system cancer	0.00291	0.00291	CcSEcCtD
Methyldopa—Pancreatitis—Methotrexate—lymphatic system cancer	0.00289	0.00289	CcSEcCtD
Methyldopa—Constipation—Mitoxantrone—lymphatic system cancer	0.00287	0.00287	CcSEcCtD
Methyldopa—Body temperature increased—Carmustine—lymphatic system cancer	0.00286	0.00286	CcSEcCtD
Methyldopa—Pancytopenia—Methotrexate—lymphatic system cancer	0.0028	0.0028	CcSEcCtD
Methyldopa—Body temperature increased—Vincristine—lymphatic system cancer	0.00273	0.00273	CcSEcCtD
Methyldopa—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.00271	0.00271	CcSEcCtD
Methyldopa—Hypersensitivity—Carmustine—lymphatic system cancer	0.00266	0.00266	CcSEcCtD
Methyldopa—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00266	0.00266	CcSEcCtD
Methyldopa—Vomiting—Bleomycin—lymphatic system cancer	0.00263	0.00263	CcSEcCtD
Methyldopa—Infestation—Methotrexate—lymphatic system cancer	0.00263	0.00263	CcSEcCtD
Methyldopa—Infestation NOS—Methotrexate—lymphatic system cancer	0.00263	0.00263	CcSEcCtD
Methyldopa—Rash—Bleomycin—lymphatic system cancer	0.00261	0.00261	CcSEcCtD
Methyldopa—Dermatitis—Bleomycin—lymphatic system cancer	0.00261	0.00261	CcSEcCtD
Methyldopa—Asthenia—Carmustine—lymphatic system cancer	0.00259	0.00259	CcSEcCtD
Methyldopa—Hypersensitivity—Vincristine—lymphatic system cancer	0.00254	0.00254	CcSEcCtD
Methyldopa—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.00248	0.00248	CcSEcCtD
Methyldopa—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00248	0.00248	CcSEcCtD
Methyldopa—Asthenia—Vincristine—lymphatic system cancer	0.00248	0.00248	CcSEcCtD
Methyldopa—Diarrhoea—Carmustine—lymphatic system cancer	0.00247	0.00247	CcSEcCtD
Methyldopa—Nausea—Bleomycin—lymphatic system cancer	0.00246	0.00246	CcSEcCtD
Methyldopa—Agranulocytosis—Methotrexate—lymphatic system cancer	0.00245	0.00245	CcSEcCtD
Methyldopa—Asthenia—Mitoxantrone—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Methyldopa—Dizziness—Carmustine—lymphatic system cancer	0.00239	0.00239	CcSEcCtD
Methyldopa—Diarrhoea—Vincristine—lymphatic system cancer	0.00236	0.00236	CcSEcCtD
Methyldopa—Hepatitis—Methotrexate—lymphatic system cancer	0.00236	0.00236	CcSEcCtD
Methyldopa—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.0023	0.0023	CcSEcCtD
Methyldopa—Vomiting—Carmustine—lymphatic system cancer	0.0023	0.0023	CcSEcCtD
Methyldopa—Dizziness—Vincristine—lymphatic system cancer	0.00228	0.00228	CcSEcCtD
Methyldopa—Rash—Carmustine—lymphatic system cancer	0.00228	0.00228	CcSEcCtD
Methyldopa—Dermatitis—Carmustine—lymphatic system cancer	0.00228	0.00228	CcSEcCtD
Methyldopa—Headache—Carmustine—lymphatic system cancer	0.00226	0.00226	CcSEcCtD
Methyldopa—Vomiting—Vincristine—lymphatic system cancer	0.00219	0.00219	CcSEcCtD
Methyldopa—Cardiac disorder—Methotrexate—lymphatic system cancer	0.00219	0.00219	CcSEcCtD
Methyldopa—Rash—Vincristine—lymphatic system cancer	0.00218	0.00218	CcSEcCtD
Methyldopa—Dermatitis—Vincristine—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Methyldopa—Headache—Vincristine—lymphatic system cancer	0.00216	0.00216	CcSEcCtD
Methyldopa—Nausea—Carmustine—lymphatic system cancer	0.00215	0.00215	CcSEcCtD
Methyldopa—Angiopathy—Methotrexate—lymphatic system cancer	0.00214	0.00214	CcSEcCtD
Methyldopa—Vomiting—Mitoxantrone—lymphatic system cancer	0.00214	0.00214	CcSEcCtD
Methyldopa—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.00212	0.00212	CcSEcCtD
Methyldopa—Rash—Mitoxantrone—lymphatic system cancer	0.00212	0.00212	CcSEcCtD
Methyldopa—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00212	0.00212	CcSEcCtD
Methyldopa—Headache—Mitoxantrone—lymphatic system cancer	0.00211	0.00211	CcSEcCtD
Methyldopa—Mental disorder—Methotrexate—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Methyldopa—Nausea—Vincristine—lymphatic system cancer	0.00205	0.00205	CcSEcCtD
Methyldopa—Nausea—Mitoxantrone—lymphatic system cancer	0.002	0.002	CcSEcCtD
Methyldopa—Leukopenia—Methotrexate—lymphatic system cancer	0.00184	0.00184	CcSEcCtD
Methyldopa—Arthralgia—Methotrexate—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Methyldopa—Myalgia—Methotrexate—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Methyldopa—Infection—Methotrexate—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Methyldopa—Nervous system disorder—Methotrexate—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Methyldopa—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Methyldopa—Skin disorder—Methotrexate—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Methyldopa—Paraesthesia—Methotrexate—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Methyldopa—Body temperature increased—Methotrexate—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Methyldopa—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Methyldopa—Asthenia—Methotrexate—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Methyldopa—Diarrhoea—Methotrexate—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Methyldopa—Dizziness—Methotrexate—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Methyldopa—Vomiting—Methotrexate—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Methyldopa—Rash—Methotrexate—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Methyldopa—Dermatitis—Methotrexate—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Methyldopa—Headache—Methotrexate—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Methyldopa—Nausea—Methotrexate—lymphatic system cancer	0.000994	0.000994	CcSEcCtD
